Morgan Stanley
STRO icon

Morgan Stanley’s Sutro Biopharma STRO Stock Holding History

Morgan Stanley’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$262K Sell
10,529
-5,393
-34% -$97.5K ﹤0.01% 5752
2025
Q4 		$184K Sell
15,922
-8,267
-34% -$78.5K ﹤0.01% 5960
2025
Q3 		$210K Sell
24,189
-1,671
-6% -$14.2K ﹤0.01% 5866
2025
Q2 		$185K Buy
25,860
+6,274
+32% +$51.3K ﹤0.01% 5886
2025
Q1 		$127K Sell
19,586
-132,428
-87% -$2.09M ﹤0.01% 5910
2024
Q4 		$2.8M Buy
152,014
+124,605
+455% +$3.8M ﹤0.01% 4453
2024
Q3 		$948K Sell
27,409
-1,372
-5% -$53.8K ﹤0.01% 5074
2024
Q2 		$843K Sell
28,781
-26,156
-48% -$1.03M ﹤0.01% 5062
2024
Q1 		$3.1M Buy
54,937
+10,152
+23% +$448K ﹤0.01% 4293
2023
Q4 		$1.92M Buy
44,785
+29,459
+192% +$935K ﹤0.01% 4949
2023
Q3 		$532K Sell
15,326
-3,634
-19% -$158K ﹤0.01% 5142
2023
Q2 		$882K Buy
18,960
+4,518
+31% +$225K ﹤0.01% 4905
2023
Q1 		$667K Sell
14,442
-8,351
-37% -$530K ﹤0.01% 5091
2022
Q4 		$1.84M Sell
22,793
-10,364
-31% -$720K ﹤0.01% 4519
2022
Q3 		$1.84M Sell
33,157
-54
-0.2% -$3.2K ﹤0.01% 4498
2022
Q2 		$1.73M Sell
33,211
-708
-2% -$39.5K ﹤0.01% 4645
2022
Q1 		$2.79M Buy
33,919
+27,569
+434% +$2.62M ﹤0.01% 4258
2021
Q4 		$946K Buy
6,350
+3,736
+143% +$669K ﹤0.01% 5109
2021
Q3 		$493K Sell
2,614
-16,704
-86% -$3.18M ﹤0.01% 5506
2021
Q2 		$3.59M Sell
19,318
-57,993
-75% -$11.4M ﹤0.01% 4118
2021
Q1 		$17.6M Buy
77,311
+64,149
+487% +$15.2M ﹤0.01% 2045
2020
Q4 		$2.86M Buy
13,162
+12,131
+1,177% +$2.01M ﹤0.01% 3841
2020
Q3 		$103K Buy
1,031
+441
+75% +$41.7K ﹤0.01% 5423
2020
Q2 		$46K Buy
590
+506
+602% +$48.6K ﹤0.01% 5704
2020
Q1 		$9K Sell
84
-1,676
-95% -$176K ﹤0.01% 6048
2019
Q4 		$194K Sell
1,760
-644
-27% -$66.4K ﹤0.01% 5424
2019
Q3 		$219K Buy
2,404
+2,322
+2,832% +$234K ﹤0.01% 5083
2019
Q2 		$9K Sell
82
-16
-16% -$1.76K ﹤0.01% 6169
2019
Q1 		$11K Sell
98
-882
-90% -$91.7K ﹤0.01% 6159
2018
Q4 		$88K Buy
+980
New +$118K ﹤0.01% 5599

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley's STRO Position: Q1 2026 in Review

Morgan Stanley reduced its Sutro Biopharma (STRO) stake by 34% in Q1 2026, selling an estimated $97.5K and leaving 10,529 shares worth $262K. The position accounts for ﹤0.01% of the portfolio, ranked #5752.

Morgan Stanley first reported a position in STRO in Q4 2018 and has held it in 30 quarters since. The position peaked at $17.6M in Q1 2021. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Morgan Stanley held 10,529 shares of Sutro Biopharma worth $262K as of Q1 2026.
  • Morgan Stanley sold 5,393 Sutro Biopharma shares in Q1 2026, an estimated $97.5K.
  • Sutro Biopharma made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5752 holding.
  • Morgan Stanley first reported a position in Sutro Biopharma in Q4 2018 and has held it in 30 quarters since.
  • Morgan Stanley's Sutro Biopharma position peaked at $17.6M in Q1 2021.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.